Literature DB >> 21536754

Inhibition of neuronal voltage-gated sodium channels by brilliant blue G.

Sooyeon Jo1, Bruce P Bean.   

Abstract

Brilliant blue G (BBG), best known as an antagonist of P2X7 receptors, was found to inhibit voltage-gated sodium currents in N1E-115 neuroblastoma cells. Sodium currents elicited from a holding potential of -60 mV were blocked with an IC(50) of 2 μM. Block was enhanced in a use-dependent manner at higher stimulation rates. The voltage-dependence of inactivation was shifted in the hyperpolarizing direction, and recovery from inactivation was slowed by BBG. The most dramatic effect of BBG was to slow recovery from inactivation after long depolarizations, with 3 μM BBG increasing half-time for recovery (measured at -120 mV) from 24 to 854 ms after a 10-s step to 0 mV. These results were mimicked by a kinetic model in which BBG binds weakly to resting channels (K(d) = 170 μM) but tightly to fast-inactivated channels (K(d) = 5 μM) and even more tightly (K(d) = 0.2 μM) to slow-inactivated channels. In contrast to BBG, the structurally related food-coloring dye Brilliant Blue FCF had very little effect at concentrations up to 30 μM. These results show that BBG inhibits voltage-gated sodium channels at micromolar concentrations. Although BBG inhibition of sodium channels is less potent than inhibition of P2X7 receptors, there may be significant inhibition of sodium channels at BBG concentrations achieved in spinal cord or brain during experimental treatment of spinal cord injury or Huntington's disease. Considered as a sodium channel blocker, BBG is remarkably potent, acting with more than 10-fold greater potency than lacosamide, another blocker thought to bind to slow-inactivated channels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536754      PMCID: PMC3141889          DOI: 10.1124/mol.110.070276

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  39 in total

1.  A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation.

Authors:  J W West; D E Patton; T Scheuer; Y Wang; A L Goldin; W A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 2.  Voltage-gated sodium channels and pain pathways.

Authors:  John N Wood; James P Boorman; Kenji Okuse; Mark D Baker
Journal:  J Neurobiol       Date:  2004-10

3.  Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels.

Authors:  D S Ragsdale; J C McPhee; T Scheuer; W A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

4.  Sodium channel alpha-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): different expression patterns in developing rat nervous system.

Authors:  P A Felts; S Yokoyama; S Dib-Hajj; J A Black; S G Waxman
Journal:  Brain Res Mol Brain Res       Date:  1997-04

5.  Na+ channels must deactivate to recover from inactivation.

Authors:  C C Kuo; B P Bean
Journal:  Neuron       Date:  1994-04       Impact factor: 17.173

6.  Distribution of I, II and III subtypes of voltage-sensitive Na+ channel mRNA in the rat brain.

Authors:  T Furuyama; Y Morita; S Inagaki; H Takagi
Journal:  Brain Res Mol Brain Res       Date:  1993-01

7.  Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons.

Authors:  C C Kuo; B P Bean
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

8.  Lifetime toxicity/carcinogenicity studies of FD & C Blue No. 1 (brilliant blue FCF) in rats and mice.

Authors:  J F Borzelleca; K Depukat; J B Hallagan
Journal:  Food Chem Toxicol       Date:  1990-04       Impact factor: 6.023

9.  Molecular motions of the outer ring of charge of the sodium channel: do they couple to slow inactivation?

Authors:  Wei Xiong; Ronald A Li; Yanli Tian; Gordon F Tomaselli
Journal:  J Gen Physiol       Date:  2003-08-11       Impact factor: 4.086

10.  Lidocaine block of cardiac sodium channels.

Authors:  B P Bean; C J Cohen; R W Tsien
Journal:  J Gen Physiol       Date:  1983-05       Impact factor: 4.086

View more
  35 in total

1.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

2.  P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway.

Authors:  Jijun Zhao; Hongyue Wang; Chao Dai; Hongyang Wang; Hui Zhang; Yuefang Huang; Shuang Wang; Felicia Gaskin; Niansheng Yang; Shu Man Fu
Journal:  Arthritis Rheum       Date:  2013-12

3.  Intrathecal injection of brilliant blue G, a P2X7 antagonist, attenuates the exercise pressor reflex in rats.

Authors:  Juan A Estrada; Guillaume P Ducrocq; Joyce S Kim; Marc P Kaufman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-07-01       Impact factor: 3.619

4.  Block of human cardiac sodium channels by lacosamide: evidence for slow drug binding along the activation pathway.

Authors:  Ging Kuo Wang; Sho-Ya Wang
Journal:  Mol Pharmacol       Date:  2014-02-21       Impact factor: 4.436

5.  Modulation of neuronal sodium channels by the sea anemone peptide BDS-I.

Authors:  Pin Liu; Sooyeon Jo; Bruce P Bean
Journal:  J Neurophysiol       Date:  2012-03-21       Impact factor: 2.714

Review 6.  P2X receptors as drug targets.

Authors:  R Alan North; Michael F Jarvis
Journal:  Mol Pharmacol       Date:  2012-12-19       Impact factor: 4.436

7.  Diverse effects of Brilliant Blue G administration in models of trigeminal activation in the rat.

Authors:  Zsuzsanna Bohár; Gábor Nagy-Grócz; Annamária Fejes-Szabó; Lilla Tar; Anna M László; Alexandra Büki; Nikolett Szabadi; Veronika Vraukó; László Vécsei; Árpád Párdutz
Journal:  J Neural Transm (Vienna)       Date:  2015-08-23       Impact factor: 3.575

8.  The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice.

Authors:  Nicholas J Geraghty; Kylie J Mansfield; Stephen J Fuller; Debbie Watson; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2017-06-08       Impact factor: 3.765

9.  Flow Synthesis and Biological Studies of an Analgesic Adamantane Derivative That Inhibits P2X7-Evoked Glutamate Release.

Authors:  Claudio Battilocchio; Lucie Guetzoyan; Chiara Cervetto; Lorenzo Di Cesare Mannelli; Daniela Frattaroli; Ian R Baxendale; Guido Maura; Antonietta Rossi; Lidia Sautebin; Mariangela Biava; Carla Ghelardini; Manuela Marcoli; Steven V Ley
Journal:  ACS Med Chem Lett       Date:  2013-05-22       Impact factor: 4.345

10.  Lidocaine Binding Enhances Inhibition of Nav1.7 Channels by the Sulfonamide PF-05089771.

Authors:  Sooyeon Jo; Bruce P Bean
Journal:  Mol Pharmacol       Date:  2020-03-19       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.